Patents Assigned to Respivert Ltd.
  • QUINAZOLIN-4 (3H)- ONE DERIVATIVES USED AS P13 KINASE INHIBITORS
    Publication number: 20160222019
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Quinazolin-4 (3H)—one derivatives used as P13 kinase inhibitors
    Patent number: 9340545
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: May 17, 2016
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Novel Compounds
    Publication number: 20160115152
    Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.
    Type: Application
    Filed: January 6, 2016
    Publication date: April 28, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Ito Kazuhiro, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • Compounds
    Patent number: 9321773
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Phosphoinositide 3-Kinase Inhibitors
    Publication number: 20160090389
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 31, 2016
    Applicant: Respivert Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • P38 MAP kinase inhibitors
    Patent number: 9260410
    Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: February 16, 2016
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • P38MAP kinase inhibitors
    Patent number: 9242960
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: January 26, 2016
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron
  • 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- I - YL) UREAS AS P38 MAPKINASE INHIBITORS
    Publication number: 20160009695
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 14, 2016
    Applicant: RESPIVERT LTD.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • Phosphoinositide 3-kinase inhibitors
    Patent number: 9227977
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 5, 2016
    Assignee: Respivert Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
    Patent number: 9108950
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: August 18, 2015
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (RSV) infection
    Patent number: 9079893
    Abstract: Medicinal use The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of respiratory syncitial virus (RSV) infection in particular viral exacerbation of a respiratory disorder such as bronchitis, asthma, COPD and/or cystic fibrosis, methods of treating or preventing RSV infection employing said compounds or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 14, 2015
    Assignee: Respivert, Ltd.
    Inventors: Lindsey Cass, Kazuhiro Ito, William Garth Rapeport, Peter Strong
  • P38 MAP kinase inhibitors
    Patent number: 9024041
    Abstract: There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: May 5, 2015
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Peter John Murray, Jonathan Gareth Williams, Ildiko Buck, Stuart Thomas Onions
  • P38 MAP kinase inhibitors
    Patent number: 8975285
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: March 10, 2015
    Assignee: Respivert Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
  • Respiratory formulations and compounds for use therein
    Patent number: 8933228
    Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: January 13, 2015
    Assignee: Respivert, Ltd.
    Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
  • COMPOUND
    Publication number: 20140274980
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: RESPIVERT LTD.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • COMPOUNDS
    Publication number: 20140249164
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Application
    Filed: March 20, 2014
    Publication date: September 4, 2014
    Applicant: Respivert Ltd
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • P38MAP KINASE INHIBITORS
    Publication number: 20140228410
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 14, 2014
    Applicant: Respivert Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart ONIONS, Catherine Elisabeth Charron
  • PI3 kinase inhibitors
    Patent number: 8741909
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the compounds.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: June 3, 2014
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • P38 MAP KINASE INHIBITORS
    Publication number: 20140114064
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.
    Type: Application
    Filed: December 24, 2013
    Publication date: April 24, 2014
    Applicant: Respivert Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
  • P38MAP kinase inhibitor
    Patent number: 8642773
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: February 4, 2014
    Assignee: Respivert Ltd.
    Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron